The FIRELIGHT-1 Trial
Sponsor:
Day One Biopharmaceuticals, Inc.
Status:
Currently enrolling patients
Condition:
Solid tumors with known activating BRAF fusions or CRAF/RAF1 fusions or amplifications
Intervention:
Tovorafenib monotherapy
Phase:
2
NCT Number:
NCT04985604
Sponsor:
Day One Biopharmaceuticals, Inc.
Status:
Currently enrolling patients
Condition:
Solid tumors with MAPK pathway alterations
Intervention:
Tovorafenib in combination with Pimasertib, an investigational MEK1 and MEK2 inhibitor
Phase:
1b/2
NCT Number:
NCT04985604
Trial sites are currently active in the following locations
VIEW TRIAL LOCATIONS